Ribosomal protein S6 mRNA is a biomarker upregulated in multiple sclerosis, downregulated by interferon treatment, and affected by season

Multiple Sclerosis Journal

Volumn 20, Issue 6, 2014, Pages 675-685

  Parnell, Grant P ^a   Gatt, Prudence N ^a   McKay, Fiona C ^a   Schibeci, Stephen ^a   Krupa, Malgorzata ^a   Powell, Joseph E ^c   Visscher, Peter M ^c   Montgomery, Grant W ^c   Lechner Scott, Jeannette ^d   Broadley, Simon ^e   Liddle, Christopher ^a   Slee, Mark ^b   Vucic, Steve ^f   Stewart, Graeme J ^a   Booth, David R ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

^e GRIFFITH UNIVERSITY   (Australia)

^f University of Sydney   (Australia)

Author keywords

biomarkers; interferon beta; Multiple sclerosis; RPS6; season

Indexed keywords

BETA INTERFERON; MESSENGER RNA; PROTEIN S6; TRANSCRIPTOME; BIOLOGICAL MARKER; IMMUNOLOGIC FACTOR; RNA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HERITABILITY; HUMAN; MALE; MULTIPLE SCLEROSIS; RNA SEQUENCE; SEASON; T LYMPHOCYTE ACTIVATION; ULTRAVIOLET RADIATION; UPREGULATION; COHORT ANALYSIS; DISEASE PREDISPOSITION; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN TARGETING; SUMMER; TREATMENT RESPONSE; WINTER; BLOOD; GENETICS; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADULT; BIOLOGICAL MARKERS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; RIBOSOMAL PROTEIN S6; RNA; RNA, MESSENGER; SEASONS; YOUNG ADULT;

EID: 84899106521     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513507819     Document Type: Article

References (35)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008 ; 372: 1502-1517
2. Bielekova B, Becker BL. Monoclonal antibodies in MS: Mechanisms of action. Neurology. 2010 ; 74: S31 - S40
3. Mehling M, Kappos L, Derfuss T. Fingolimod for multiple sclerosis: Mechanism of action, clinical outcomes, and future directions. Curr Neurol Neurosci Rep. 2011 ; 11: 492-497
4. Sawcer S, Hellenthal G, Pirinen M, et al. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011 ; 476: 214-219
5. Gandhi KS, McKay FC, Cox M, et al. The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis. Hum Mol Genet. 2010 ; 19: 2134-2143
6. Joehanes R, Johnson AD, Barb JJ, et al. Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham Heart Study. Physiol Genomics. 2012 ; 44: 59-75
7. Stuve O, Ransohoff RM. Immunotherapy for multiple sclerosis: The curious case of interferon beta. Arch Neurol. 2009 ; 66: 1193-1194
8. Powell JE, Henders AK, McRae AF, et al. Genetic control of gene expression in whole blood and lymphoblastoid cell lines is largely independent. Genome Res. 2012 ; 22: 456-466
9. McKay F, Schibeci S, Heard R, et al. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: A comparison of three methods in a large Australasian cohort. J Immunol Methods. 2006 ; 310: 20-29
10. Trapnell C, Pachter L, Salzberg SL. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics. 2009 ; 25: 1105-1111
11. Xu G, Deng N, Zhao Z, Judeh T, et al. SAMMate: A GUI tool for processing short read alignments in SAM/BAM format. Source Code Biol Med. 2011 ; 6: 2
12. Simon R, Lam A, Li M-C, et al. Analysis of gene expression data using BRB-Array tools. Cancer Informatics. 2007 ; 3: 11-17
13. Powell JE, Henders AK, McRae AF, et al. The Brisbane Systems Genetics Study: Genetical genomics meets complex trait genetics. PLoS ONE. 2012 ; 7: e35430
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001 ; 25: 402-408
15. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010 ; 26: 139-140
16. Hintzen R. Multiple sclerosis: Month of birth effect in MS-fact or artefact?. Nat Rev Neurol. 2013 ; 9: 489-490
17. Liu SM, Xavier R, Good KL, et al. Immune cell transcriptome datasets reveal novel leukocyte subset-specific genes and genes associated with allergic processes. J Allergy Clin Immunol. 2006 ; 118: 496-503
18. Su AI, Wiltshire T, Batalov S, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004 ; 101: 6062-6067
19. Gilmour AR, Thompson R, Cullis BR. Average information REML: An efficient algorithm for variance parameter estimation in linear mixed models. Biometrics. 1995 ; 51: 1440-1450
20. Perry RP. Balanced production of ribosomal proteins. Gene. 2007 ; 401: 1-3
21. Zimmermann RA. The double life of ribosomal proteins. Cell. 2003 ; 115: 130-132
22. Rosner M, Schipany K, Hengstschlager M. Spatial consequences of blocking mTOR/S6K: Relevance for therapy. Cell Cycle. 2012 ; 11: 420-421
23. Salmond RJ, Emery J, Okkenhaug K, et al. MAPK, phosphatidylinositol 3-kinase, and mammalian target of rapamycin pathways converge at the level of ribosomal protein S6 phosphorylation to control metabolic signaling in CD8 T cells. J Immunol. 2009 ; 183: 7388-7397
24. Perl AE, Kasner MT, Shank D, et al. Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res. 2012 ; 18: 1716-1725
25. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 2004 ; 64: 252-261
26. Achiron A, Feldman A, Magalashvili D, et al. Suppressed RNA-polymerase 1 pathway is associated with benign multiple sclerosis. PLoS ONE. 2012 ; 7: e46871
27. Cobbold SP, Adams E, Nolan KF, et al. Connecting the mechanisms of T-cell regulation: Dendritic cells as the missing link. Immunol Rev. 2010 ; 236: 203-218
28. Jin Y, de Pedro-Cuesta J, Soderstrom M, et al. Seasonal patterns in optic neuritis and multiple sclerosis: A meta-analysis. J Neurol Sci. 2000 ; 181: 56-64
29. Simpson S, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010 ; 68: 193-203
30. Maes M, Stevens W, Scharpe S, et al. Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6, and soluble interleukin-2 and -6 receptor concentrations in normal volunteers. Experientia. 1994 ; 50: 821-829
31. Khoo AL, Koenen HJ, Chai LY, et al. Seasonal variation in vitamin D(3) levels is paralleled by changes in the peripheral blood human T cell compartment. PLoS ONE. 2012 ; 7: e29250
32. Hart PH. Vitamin D supplementation, moderate sun exposure, and control of immune diseases. Discov Med. 2012 ; 13: 397-404
33. Dhib-Jalbut S, Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology. 2010 ; 74: S17 - S24
34. Kantor AB, Deng J, Waubant E, et al. Identification of short-term pharmacodynamic effects of interferon-beta-1a in multiple sclerosis subjects with broad- based phenotypic profiling. J Neuroimmunol. 2007 ; 188: 103-116
35. Blumberg RS, Dittel B, Hafler D, et al. Unraveling the autoimmune translational research process layer by layer. Nat Med. 2012 ; 18: 35-41